Close



Feb 29, 2024 10:02AM
Feb 27, 2024 06:02AM
Feb 27, 2024 06:00AM
Feb 26, 2024 06:00AM
Nov 9, 2023 04:01PM
Sep 19, 2023 06:15AM
Sep 19, 2023 06:15AM BeiGene Announces Positive Regulatory Updates in Europe and the U.S. After Recently Regaining Global Rights for TEVIMBRA®
Aug 2, 2023 06:00AM
Jul 12, 2023 07:03AM
Jul 12, 2023 07:00AM
Nov 9, 2022 07:00AM
Aug 4, 2022 07:00AM
Jul 14, 2022 06:00AM
Jul 14, 2022 06:00AM BeiGene Provides Regulatory Update on the U.S. Biologics License Application (BLA) for PD-1 Inhibitor Tislelizumab in 2L ESCC
Jun 22, 2022 07:21AM
Jun 13, 2022 07:00AM
Jun 13, 2022 07:00AM
May 5, 2022 07:00AM
Apr 11, 2022 06:01AM
Apr 11, 2022 06:00AM
Mar 11, 2022 07:01AM BeiGene (BGNE) Announces China NMPA Approves Tislelizumab for Patients with Microsatellite Instability-High or Mismatch Repair-Deficient Solid Tumors
Mar 11, 2022 07:00AM
Feb 25, 2022 07:00AM
Feb 22, 2022 07:01AM
Feb 22, 2022 07:01AM
Feb 22, 2022 07:00AM
Jan 24, 2022 05:52AM
Jan 24, 2022 05:00AM BeiGene Announces Positive Findings from Phase 3 Trial of Tislelizumab in Combination with Chemotherapy in First-Line Gastric or Gastroesophageal Junction Cancer
Jan 6, 2022 06:38AM
Jan 6, 2022 03:30AM
Dec 20, 2021 06:15AM
Dec 20, 2021 06:15AM
Dec 10, 2021 06:15AM
Dec 10, 2021 03:00AM
Dec 3, 2021 05:36AM BeiGene (BGNE) Reports Inclusion in China National Reimbursement Drug List of Tislelizumab in Three New Indications, BRUKINSA in One New Indication, and the First Listing for Pamiparib
Dec 2, 2021 11:00PM
Nov 4, 2021 04:05PM
Sep 13, 2021 06:18AM
Sep 13, 2021 12:00AM
Aug 5, 2021 04:05PM
May 19, 2021 07:01AM
May 19, 2021 07:00AM BeiGene Announces U.S. FDA Acceptance and Priority Review of Supplemental New Drug Application for BRUKINSA® (Zanubrutinib) in Marginal Zone Lymphoma
Feb 25, 2021 04:05PM
Feb 17, 2021 07:05AM
Feb 17, 2021 07:00AM
Nov 12, 2019 04:05PM
Aug 21, 2019 04:30PM
Jul 27, 2017 07:30AM

12,341 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All